As always, here are this morning's top media headline summaries from Reuters, WSJ, NYTimes, FT, Bloomberg, and more. This morning's top day trader and active trader alerts are in GERN, STEM, OPXA, HGSI, DRYS, ABK, MBI, TRGT. The top 10 analyst upgrades, downgrades, and initiations were in AMZN, AAPL, AGO, BAC, CELG, CBST, DRYS, EBAY, POT, and RIG. The topstock and market rumors are out and will be updated throughout the trading day.
Speaking of Amazon.com (AMZN), Jim Cramer came out with a whopping $214 fair value for Amazon.com. While we love the company and believe it may still have upside, this was only the rosy side of the coin and took almost none of the risks into assumption. Cramer's call also used assumptions that were very far above the real estimates in his quest to be the top call in the stock.
We did a long detailed piece on brands and companies at risk of disappearing in 2010, all of which are of course US public companies. Depending upon how you count our list from a year ago predicting which brands would drop off or change drastically, 4 of 10 of those are now gone. Not all of course go under, because many are bought for pennies on the dollar.
At BioHealthInvestor.com yesterday we caught the Stem Cell stocks before they moved on the new stem cell lines being approved. While these are giving back gains today, we would like to point out thet the NIH said it would be making decisions on new stem cell line approvals by DEC 4. This should keep volatility up for traders, and it should be there through the end of this week.
Speaking of Amazon.com (AMZN), Jim Cramer came out with a whopping $214 fair value for Amazon.com. While we love the company and believe it may still have upside, this was only the rosy side of the coin and took almost none of the risks into assumption. Cramer's call also used assumptions that were very far above the real estimates in his quest to be the top call in the stock.
We did a long detailed piece on brands and companies at risk of disappearing in 2010, all of which are of course US public companies. Depending upon how you count our list from a year ago predicting which brands would drop off or change drastically, 4 of 10 of those are now gone. Not all of course go under, because many are bought for pennies on the dollar.
At BioHealthInvestor.com yesterday we caught the Stem Cell stocks before they moved on the new stem cell lines being approved. While these are giving back gains today, we would like to point out thet the NIH said it would be making decisions on new stem cell line approvals by DEC 4. This should keep volatility up for traders, and it should be there through the end of this week.
Goldman Sachs (GS) is appraently explaining its big bonuses to larger shareholders.
For the index-arb players, we took a look at the implications of AOL not being in the S&P 500 as its parent Time Warner is. This might have been a larger deal, but our take is that the street will easily be able to absorb the TWX selling by S&P index funds.
For the index-arb players, we took a look at the implications of AOL not being in the S&P 500 as its parent Time Warner is. This might have been a larger deal, but our take is that the street will easily be able to absorb the TWX selling by S&P index funds.
No comments:
Post a Comment